Atea Pharmaceuticals Income Statement (2019-2026) | AVIR

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
60.39M32.81M192.18M
Operating items
Research & Development (Quarter)
39.80M43.02M57.81M29.63M19.86M4.91M27.54M28.95M22.06M28.18M35.05M57.58M34.70M26.16M25.67M29.58M32.27M38.35M47.82M41.13M
Selling, General & Administrative (Quarter)
11.90M11.94M13.19M12.54M12.44M11.38M12.36M12.62M13.17M12.60M11.53M12.23M12.22M11.04M13.36M9.46M9.07M7.22M7.12M6.87M
Operating Expenses (Quarter)
51.70M54.96M71.00M42.17M32.30M16.28M39.90M41.57M35.23M40.78M46.57M69.81M46.92M37.20M39.03M39.04M41.34M45.57M54.93M48.01M
Operating Income (Quarter)
8.69M-22.15M121.18M-42.17M-32.30M-16.28M-39.90M-41.57M-35.23M-40.78M-46.57M-69.81M-46.92M-37.20M-39.03M-39.04M-41.34M-45.57M-54.93M-48.01M
EBIT (Quarter)
8.69M-22.15M121.18M-42.17M-32.30M-16.28M-39.90M-41.57M-35.23M-40.78M-46.57M-69.81M-46.92M-37.20M-39.03M-39.04M-41.34M-45.57M-54.93M-48.01M
Non-operating items
Interest & Investment Income (Quarter)
0.05M0.05M0.05M0.10M1.08M4.38M5.59M6.30M7.30M7.86M7.76M6.87M6.64M6.28M5.71M4.97M4.39M3.71M3.30M2.62M
Net income details
EBT (Quarter)
8.74M-22.09M121.23M-42.08M-31.21M-11.90M-34.31M-35.27M-27.93M-32.92M-38.81M-62.94M-40.28M-30.93M-33.32M-34.07M-36.95M-41.85M-51.63M-45.39M
Tax Provisions (Quarter)
7.20M6.10M4.10M0.12M-3.83M0.12M0.20M0.25M0.22M0.35M0.23M0.24M0.23M0.23M0.20M0.21M0.20M-6.77M0.05M
Profit After Tax (Quarter)
1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M
Income from Continuing Operations (Quarter)
1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M
Consolidated Net Income (Quarter)
1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M
Income towards Parent Company (Quarter)
1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M
Net Income towards Common Stockholders (Quarter)
1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M
Additional items
EPS (Basic) (Quarter)
0.02-0.341.41-0.51-0.38-0.10-0.41-0.43-0.34-0.40-0.47-0.75-0.48-0.37-0.40-0.40-0.44-0.53-0.57-0.57
EPS (Weighted Average and Diluted) (Quarter)
0.02-0.341.32-0.51-0.38-0.10-0.41-0.43-0.34-0.40-0.47-0.75-0.48-0.37-0.40-0.40-0.44-0.53-0.57-0.57
Shares Outstanding (Weighted Average) (Quarter)
82.74M82.82M82.82M83.18M83.22M83.23M83.25M83.33M83.40M83.37M83.39M83.92M84.07M84.20M84.26M85.16M83.75M79.05M81.50M79.20M
EBITDA (Quarter)
8.69M-28.19M117.13M-42.08M-31.34M-8.92M-34.26M-35.09M-28.19M-33.09M-38.70M-63.56M-40.62M-30.23M-33.95M-34.39M-37.24M-41.85M-44.93M-45.71M
Shares Outstanding (Quarter)
82.78M83.05M83.10M83.26M83.26M83.29M83.29M83.40M83.40M83.44M83.44M84.22M84.42M84.46M84.46M85.58M81.14M78.13M78.13M80.03M
Tax Rate (Quarter)
82.39-27.613.38-0.3832.21-0.36-0.56-0.90-0.67-0.90-0.37-0.60-0.73-0.68-0.60-0.56-0.4713.11-0.11